Redeye returns with a research update on Nanologica following its Q3 2023 report, which were soft in terms of sales but in line with our EBIT estimate. With an eventful period in terms of customer activity, we see an exciting period ahead.
ANNONS
Redeye returns with a research update on Nanologica following its Q3 2023 report, which were soft in terms of sales but in line with our EBIT estimate. With an eventful period in terms of customer activity, we see an exciting period ahead.